ABCL vs STT · rev $12.4M vs P/E 17, rev $7.84B
Abcellera Biologics Inc (ABCL) versus State Street Corp (STT) — a side-by-side from cached financials, not a winner call.
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
State Street Corp (STT) is a asset management company listed on US.
Latest reported ABCL revenue for 2026-06-30 was $12.4M. Net income was -$98.6M. Revenue was up 48.7% from 2026-03-31 to 2026-06-30. ABCL currently screens at market cap $1.12B.
Latest reported STT revenue for 2026-06-30 was $7.84B. Net income was $1.85B. STT currently screens at market cap $45.02B and trailing P/E 16.5.
ABCL currently screens at market cap $1.12B. STT currently screens at market cap $45.02B and trailing P/E 16.5.
Not investment advice. Open the ABCL and STT stock pages for the full models.
Not investment advice.